ArticleInnere Medizin (Heidelberg, Germany)2026
[Functional assessment and medication in older adults].
Article in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive geriatric assessment (CGA) and targeted functional assessments have become indispensable tools for safe and effective pharmacotherapy in older adults. Chronological age alone is a poor predictor of drug response and adverse outcomes; in contrast, CGA reliably detects frailty, cognitive impairment, and motor dysfunction-key determinants of pharmacokinetic and pharmacodynamic changes, as well as vulnerability to delirium, falls, and functional decline. By integrating validated instruments (e.g., frailty indexes, neuropsychological tests, the Timed-Up-and-Go test, gait speed, and handgrip strength), CGA unmasks subclinical deficits and quantifies individual risk profiles that directly influence clinical decisions: initiation, dosing, choice of agent, and, in particular, deprescribing of high-risk medications (anticholinergics, benzodiazepines, and fall-risk increasing drugs [FRID]). There is a large body of evidence demonstrating that CGA-guided prescribing reduces serious adverse drug reactions, falls, hospitalisations, and mortality while improving quality of life. In an era of increasingly complex regimens, systematic functional assessment in older people is no longer optional-it is the cornerstone of personalised, evidence-based pharmacotherapy in geriatric medicine.
Indexed as
Identifiers
41701266What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.